Guggenheim Increases National Vision (NASDAQ:EYE) Price Target to $33.00

National Vision (NASDAQ:EYE) had its price target boosted by research analysts at Guggenheim from $32.00 to $33.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Guggenheim’s price target would indicate a potential upside of 13.13% from the stock’s current price.

Several other brokerages have also weighed in on EYE. Barclays raised their target price on National Vision from $30.00 to $32.00 and gave the stock an “overweight” rating in a research report on Monday. National Bank Financial set a $32.00 price objective on shares of National Vision in a report on Tuesday, December 9th. Citigroup boosted their price objective on shares of National Vision from $29.00 to $35.00 and gave the stock a “buy” rating in a research report on Tuesday, November 18th. UBS Group dropped their target price on shares of National Vision from $41.00 to $39.00 and set a “buy” rating on the stock in a research report on Tuesday, November 18th. Finally, Wolfe Research set a $35.00 price target on shares of National Vision in a research report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $29.69.

National Vision Trading Up 0.4%

Shares of NASDAQ:EYE opened at $29.17 on Thursday. National Vision has a 52 week low of $10.45 and a 52 week high of $30.02. The company’s 50 day moving average is $27.20 and its two-hundred day moving average is $26.54. The company has a market cap of $2.31 billion, a PE ratio of -972.01, a P/E/G ratio of 1.52 and a beta of 1.38. The company has a current ratio of 0.53, a quick ratio of 0.32 and a debt-to-equity ratio of 0.28.

National Vision (NASDAQ:EYE) last issued its earnings results on Wednesday, March 4th. The company reported $0.15 EPS for the quarter, topping analysts’ consensus estimates of $0.05 by $0.10. National Vision had a negative net margin of 0.12% and a positive return on equity of 3.58%. The firm had revenue of $503.41 million during the quarter, compared to the consensus estimate of $495.26 million. During the same quarter in the previous year, the firm posted ($0.04) earnings per share. The company’s revenue was up 15.1% compared to the same quarter last year. National Vision has set its FY 2026 guidance at 0.850-1.090 EPS. Equities analysts predict that National Vision will post 0.31 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of EYE. Asset Management One Co. Ltd. purchased a new position in National Vision during the 3rd quarter worth $4,090,000. Allianz Asset Management GmbH acquired a new position in shares of National Vision during the third quarter worth about $8,390,000. Public Sector Pension Investment Board raised its holdings in National Vision by 14.6% during the third quarter. Public Sector Pension Investment Board now owns 308,942 shares of the company’s stock worth $9,018,000 after purchasing an additional 39,394 shares in the last quarter. Jupiter Asset Management Ltd. lifted its position in National Vision by 4,726.8% in the third quarter. Jupiter Asset Management Ltd. now owns 977,525 shares of the company’s stock valued at $28,534,000 after purchasing an additional 957,273 shares during the period. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in National Vision in the 3rd quarter valued at approximately $747,000.

National Vision News Summary

Here are the key news stories impacting National Vision this week:

• Positive Sentiment: Q4 beat on EPS and revenue with margin improvement — National Vision reported $0.15 EPS (vs. ~ $0.05–$0.06 consensus) and $503.4M in revenue, with management citing stronger traffic and average ticket growth that helped expand margins. EYE Stock Up Following Q4 Earnings & Revenue Beat, Margins Rise
• Positive Sentiment: FY2026 EPS guidance topped consensus — Management set FY26 EPS at $0.85–$1.09, above the Street midpoint, giving investors a clearer near-term earnings outlook. The guidance contributed to investor enthusiasm despite other mixed elements. National Vision Holdings, Inc. Reports Fourth Quarter and Fiscal 2025 Financial Results
• Neutral Sentiment: Earnings call transcript available — Details and management commentary from the Q&A are published for investors who want to dig into drivers (store-level trends, margin levers, marketing cadence). National Vision Holdings, Inc. (EYE) Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Slide deck and presentation posted — Management’s slides provide the company’s KPIs and outlook assumptions if you want to model FY26 under different revenue/margin scenarios. National Vision Holdings, Inc. 2025 Q4 – Results – Earnings Call Presentation
• Negative Sentiment: Revenue guidance seen as soft by some — The FY26 revenue range ($2.0B–$2.1B) was viewed as slightly light versus the Street, and reports flagged that the “soft guidance” headline pressured sentiment for some investors. That caution partly offset the beat and contributed to mixed market reactions. National Vision beats estimates, but shares edge down on soft guidance

National Vision Company Profile

National Vision Holdings, Inc is an American optical retailer specializing in accessible vision care and eyewear. The company operates under multiple retail banners, offering comprehensive eye health services and a wide range of optical products. Since its founding in the early 1990s, National Vision has focused on providing value-driven solutions, targeting underserved and price‐conscious consumer segments.

Through its primary retail brands—including America’s Best Contacts & Eyeglasses, Eyeglass World, Optical America and Vista Optical—National Vision delivers services such as comprehensive eye examinations, prescription eyewear, contact lenses, sunglasses and lens accessories.